search
Back to results

Mineralocorticoid Receptor Antagonists in Type 2 Diabetes

Primary Purpose

Diabetes Type 2

Status
Completed
Phase
Phase 4
Locations
Denmark
Study Type
Interventional
Intervention
Eplerenone
Placebo
Sponsored by
Herlev Hospital
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Diabetes Type 2

Eligibility Criteria

18 Years - 85 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Able to understand the written patient information and to give informed consent
  • Type 2 diabetes mellitus (WHO criteria), diagnosed at least 3 months prior to baseline
  • Blood pressure treatment according to standard guidelines
  • Negative pregnancy test (fertile women)
  • Be willing to change/pause potassium sparing medication
  • Age 18-85 years
  • Patients must have high cardiovascular risk factors, defined as one of the following:

NT-proBNP ≥ 70 pg/ml (taken within the last 6 months prior to baseline) Albuminuria ( albumin/creatinine ratio ≥ 30 mg/g Confirmed history of myocardial infarction (≥ 3 months prior to baseline) Or patient discharged from hospital with a documented diagnosis of unstable angina within 24 months prior to baseline Evidence of coronary artery disease by CAG in 1 or more major coronary arteries OR at least one of the following: a positive noninvasive stress test, OR a positive stress echocardiography showing regional systolic wall motion abnormalities, OR a positive scintigraphy test showing stress-induced ischemia History of ischemic or hemorrhagic stroke (≥ 3 months prior to informed consent) Presence of peripheral artery disease (symptomatic or not ) documented by either: previous limb angioplasty, stenting or bypass surgery; or previous limb or foot amputation due to circulatory insufficiency; or angiographic evidence of significant (≥ 50%) peripheral artery stenosis in at least one limb; or evidence from a non-invasive measurement of significant (≥50% or as reported as hemodynamically significant) peripheral artery stenosis in at least one limb; or ankle brachial index of ≤ 0.9

Left ventricle hypertrophy:

Documented at echocardiography ECG: R-spike in V5/V6 ≥ 25 mm or S-spike in V1 + R-spike in V5/V6 ≥ 35 mm Patients both with and without a cardiovascular risk factor can be randomized to the fat biopsy sub study.

Exclusion Criteria:

  • Allergic to the study medication
  • Systolic HF (LVEF ≤ 40%)
  • Impaired kidney function, eGFR ≤ 40 ml/min
  • Severe liver insufficiency (Child-Pugh class C)
  • Treatment with MR antagonist within 3 months prior to baseline
  • Treatment with both ACE inhibitors and Angiotensin II Receptor blockers.
  • Serum-potassium ≥ 5.0 mmol/l
  • Serum-sodium ≤ 135 mmol/l
  • Myocardial infarction, unstable angina pectoris or bypass graft surgery within 3 months prior to baseline
  • Persistant atrial fibrillation (except for the fat biopsy sub population)
  • ECG showing malign ventricular arrhythmia or prolonged QT-interval (> 500ms)
  • Untreated heart valve disease
  • ICD-unit/pacemaker
  • Pregnancy or desire hereof or breastfeeding
  • Women in the fertile age not using safe contraceptives (spiral, hormonal contraceptives)
  • Cancer unless complete remission ≥ 5 year
  • Alcohol-/drug-abuse
  • Inflammatory bowel disease
  • Other concomitant disease or treatment that according to the investigator's assessment makes the patient unsuitable to participate in the study
  • Simultaneous participation in another clinical study
  • Treatment with CYP3A4-inhibitors (e.g. itraconazol, etoconazol, ritonavir, nelfinavir, clarithromycin, telithromycin and nefazodon)

Sites / Locations

  • Herlev and Gentofte Hospital, Department of Endocrinology and Metabolism, Department of internal medicine,

Arms of the Study

Arm 1

Arm 2

Arm Type

Active Comparator

Placebo Comparator

Arm Label

Eplerenone

placebo

Arm Description

Eplerenone 50 mg tablets. 2-4 tablets once daily for 26 weeks

sugar pill manufactured to mimic Eplerenone 50 mg tablet. 2-4 tablets once daily for 26 weeks.

Outcomes

Primary Outcome Measures

Liver fat content
changes in liver fat content by proton MR spectroscopy

Secondary Outcome Measures

Fat mass distribution
Changes in body fat distribution (total body fat, visceral fat, subcutaneous fat)
insulin resistance
Changes in insulin resistance by HOMA and Matsuda index
Urinary albumin/creatinine ratio
changes in Urinary albumin/creatinine ratio
Biomarkers of adipocyte function
Changes in biomarkers of adipocyte function (adiponectin, leptin, FGF-21, TNF-alfa, FFA, IL-6, MCP-1, MAC-1)
24 Hour blood pressure
changes in 24 Hour blood pressure
Global longitudinal strain (GLS)
changes in global longitudinal strain by echocardiography
systolic and diastolic function og left ventricule
changes in systolic and diastolic function of left ventricule by echocardiography
Regional and global fibrosis by cardiac magnetic resonance
changes in regional and global fibrosis using Late gadolineum enhancement cardiac magnetic resonance
biomarkers of myocardial stress and fibrosis
changes in biomarkers of myocardial stress and fibrosis (NT-proBNP, MR-proANP, galectin-3, GDF-15, MR-proADM)
pulse wave analysis
changes in pulse wave analysis
Quality of life
changes in quality of life using WHO-5
Diabetes related changes in quality of life
changes in quality of life using W-BQ12
kidney function
changes in creatinine and eGFR
potassium
changes in potassium

Full Information

First Posted
June 16, 2016
Last Updated
May 30, 2018
Sponsor
Herlev Hospital
search

1. Study Identification

Unique Protocol Identification Number
NCT02809963
Brief Title
Mineralocorticoid Receptor Antagonists in Type 2 Diabetes
Official Title
A Randomized, Double-blind, Placebo-controlled Study of the Effect of Mineralocorticoid Receptor Antagonists in Type 2 Diabetes Patients on Myocardial Function, Glucose and Fat Metabolism (The MIRAD-study)
Study Type
Interventional

2. Study Status

Record Verification Date
May 2018
Overall Recruitment Status
Completed
Study Start Date
November 2015 (undefined)
Primary Completion Date
November 2017 (Actual)
Study Completion Date
November 2017 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Herlev Hospital

4. Oversight

Data Monitoring Committee
Yes

5. Study Description

Brief Summary
The aim of this study is to investigate the effect of selective blocking of the mineralocorticoid receptor in patients with type 2 diabetes on insulin resistance, lipid metabolism and myocardial function.
Detailed Description
In this randomized, double-blind, placebo-controlled study we want to investigate the effect of mineralocorticoid receptor antagonists in type 2 diabetes patients on myocardial function, glucose and fat metabolism. Background The mortality rate in T2 DM is still increased by almost a factor 2 although poly pharmacological therapy of risk factors has been recommended for years. Treatment with MR antagonists in patients with primary hyperaldosteronism and systolic heart failure improves insulin resistance, myocardial function and prognosis. Further, recent evidence has suggested that aldosterone participates in the regulation of glucose and lipid metabolism, as MR expression has been identified in adipocytes and beneficial metabolic effects of selective MR blockade has been demonstrated in several animal models. Notably, there is no available data in humans with T2DM. A key feature of T2 DM is altered body composition characterized by increased metabolic active visceral adipose tissue (VAT) and increased fat content of the liver, which has been associated with cardiac dysfunction and outcome. Gold standard for measurement of VAT is magnetic resonance imaging (MRI), and proton MRI spectroscopy can quantitatively measure fat content in the liver with high precision. The pathogenesis of myocardial dysfunction in T2DM is linked with insulin resistance (IR) of adipose tissue mediating increased supply of free fatty acids and intra myocardial lipid accumulation. Thus, beneficial effects of lipid metabolism could in theory indirectly improve myocardial function in type 2 diabetics. Global longitudinal strain (GLS) is a validated method for evaluating regional and global function of the left ventricle, which is a strong predictor of incident HF in patients with myocardial infarction and closely related with plasma NT-proBNP concentrations. Hypothesis Selective blocking of the MR receptor in patients with T2 DM improves insulin resistance, lipid metabolism and myocardial function. Objectives To investigate the effect of Eplerenone 100-200 mg once daily compared to placebo in patients with type 2 diabetes with regard to glucose and lipid metabolism, myocardial function and structure, and vascular function. The primary objective is to investigate the effect of Eplerenone 100-200 mg once daily compared to placebo on changes in liver fat content. Design A single center, randomized, double blinded placebo controlled trial. Patients with T2 DM and high risk of cardiovascular disease will be randomized to either Eplerenone 100-200 mg or placebo daily for 26 weeks. Patients will be investigated at baseline and after 26 weeks. A total of 130 patients with type 2 diabetes will be included.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Diabetes Type 2

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 4
Interventional Study Model
Parallel Assignment
Masking
ParticipantInvestigator
Allocation
Randomized
Enrollment
140 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Eplerenone
Arm Type
Active Comparator
Arm Description
Eplerenone 50 mg tablets. 2-4 tablets once daily for 26 weeks
Arm Title
placebo
Arm Type
Placebo Comparator
Arm Description
sugar pill manufactured to mimic Eplerenone 50 mg tablet. 2-4 tablets once daily for 26 weeks.
Intervention Type
Drug
Intervention Name(s)
Eplerenone
Intervention Description
50 mg tablets, oral use.
Intervention Type
Drug
Intervention Name(s)
Placebo
Intervention Description
50 mg tablets, oral use
Primary Outcome Measure Information:
Title
Liver fat content
Description
changes in liver fat content by proton MR spectroscopy
Time Frame
26 weeks
Secondary Outcome Measure Information:
Title
Fat mass distribution
Description
Changes in body fat distribution (total body fat, visceral fat, subcutaneous fat)
Time Frame
26 weeks
Title
insulin resistance
Description
Changes in insulin resistance by HOMA and Matsuda index
Time Frame
26 weeks
Title
Urinary albumin/creatinine ratio
Description
changes in Urinary albumin/creatinine ratio
Time Frame
26 weeks
Title
Biomarkers of adipocyte function
Description
Changes in biomarkers of adipocyte function (adiponectin, leptin, FGF-21, TNF-alfa, FFA, IL-6, MCP-1, MAC-1)
Time Frame
26 weeks
Title
24 Hour blood pressure
Description
changes in 24 Hour blood pressure
Time Frame
26 weeks
Title
Global longitudinal strain (GLS)
Description
changes in global longitudinal strain by echocardiography
Time Frame
26 weeks
Title
systolic and diastolic function og left ventricule
Description
changes in systolic and diastolic function of left ventricule by echocardiography
Time Frame
26 weeks
Title
Regional and global fibrosis by cardiac magnetic resonance
Description
changes in regional and global fibrosis using Late gadolineum enhancement cardiac magnetic resonance
Time Frame
26 weeks
Title
biomarkers of myocardial stress and fibrosis
Description
changes in biomarkers of myocardial stress and fibrosis (NT-proBNP, MR-proANP, galectin-3, GDF-15, MR-proADM)
Time Frame
26 weeks
Title
pulse wave analysis
Description
changes in pulse wave analysis
Time Frame
26 weeks
Title
Quality of life
Description
changes in quality of life using WHO-5
Time Frame
26 weeks
Title
Diabetes related changes in quality of life
Description
changes in quality of life using W-BQ12
Time Frame
26 weeks
Title
kidney function
Description
changes in creatinine and eGFR
Time Frame
26 weeks
Title
potassium
Description
changes in potassium
Time Frame
26 weeks

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
85 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Able to understand the written patient information and to give informed consent Type 2 diabetes mellitus (WHO criteria), diagnosed at least 3 months prior to baseline Blood pressure treatment according to standard guidelines Negative pregnancy test (fertile women) Be willing to change/pause potassium sparing medication Age 18-85 years Patients must have high cardiovascular risk factors, defined as one of the following: NT-proBNP ≥ 70 pg/ml (taken within the last 6 months prior to baseline) Albuminuria ( albumin/creatinine ratio ≥ 30 mg/g Confirmed history of myocardial infarction (≥ 3 months prior to baseline) Or patient discharged from hospital with a documented diagnosis of unstable angina within 24 months prior to baseline Evidence of coronary artery disease by CAG in 1 or more major coronary arteries OR at least one of the following: a positive noninvasive stress test, OR a positive stress echocardiography showing regional systolic wall motion abnormalities, OR a positive scintigraphy test showing stress-induced ischemia History of ischemic or hemorrhagic stroke (≥ 3 months prior to informed consent) Presence of peripheral artery disease (symptomatic or not ) documented by either: previous limb angioplasty, stenting or bypass surgery; or previous limb or foot amputation due to circulatory insufficiency; or angiographic evidence of significant (≥ 50%) peripheral artery stenosis in at least one limb; or evidence from a non-invasive measurement of significant (≥50% or as reported as hemodynamically significant) peripheral artery stenosis in at least one limb; or ankle brachial index of ≤ 0.9 Left ventricle hypertrophy: Documented at echocardiography ECG: R-spike in V5/V6 ≥ 25 mm or S-spike in V1 + R-spike in V5/V6 ≥ 35 mm Patients both with and without a cardiovascular risk factor can be randomized to the fat biopsy sub study. Exclusion Criteria: Allergic to the study medication Systolic HF (LVEF ≤ 40%) Impaired kidney function, eGFR ≤ 40 ml/min Severe liver insufficiency (Child-Pugh class C) Treatment with MR antagonist within 3 months prior to baseline Treatment with both ACE inhibitors and Angiotensin II Receptor blockers. Serum-potassium ≥ 5.0 mmol/l Serum-sodium ≤ 135 mmol/l Myocardial infarction, unstable angina pectoris or bypass graft surgery within 3 months prior to baseline Persistant atrial fibrillation (except for the fat biopsy sub population) ECG showing malign ventricular arrhythmia or prolonged QT-interval (> 500ms) Untreated heart valve disease ICD-unit/pacemaker Pregnancy or desire hereof or breastfeeding Women in the fertile age not using safe contraceptives (spiral, hormonal contraceptives) Cancer unless complete remission ≥ 5 year Alcohol-/drug-abuse Inflammatory bowel disease Other concomitant disease or treatment that according to the investigator's assessment makes the patient unsuitable to participate in the study Simultaneous participation in another clinical study Treatment with CYP3A4-inhibitors (e.g. itraconazol, etoconazol, ritonavir, nelfinavir, clarithromycin, telithromycin and nefazodon)
Facility Information:
Facility Name
Herlev and Gentofte Hospital, Department of Endocrinology and Metabolism, Department of internal medicine,
City
Herlev
ZIP/Postal Code
2730
Country
Denmark

12. IPD Sharing Statement

Plan to Share IPD
No

Learn more about this trial

Mineralocorticoid Receptor Antagonists in Type 2 Diabetes

We'll reach out to this number within 24 hrs